We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Read MoreHide Full Article
Key Takeaways
Pfizer's oncology revenues grew 9% in H125 and now comprise more than 25% of total company sales.
Q3 results hinge on Xtandi, Lorbrena and Braftovi-Mektovi offsetting Ibrance's weaker performance.
Oncology biosimilars and Seagen's ADCs, including Padcev, remain pivotal growth drivers for Pfizer.
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
The addition of Seagen in 2023 strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in the first half of 2025.
Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025. Investors will be keen to know how its oncology segment performed in the third quarter when the company announces results on Nov. 4.
Pfizer’s oncology sales in the third quarter are expected to have been driven by higher sales of key drugs like Xtandi, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance.
Sales of Ibrance are likely to have declined due to continued competitive pressure across markets, generic entry in select international markets, and the impact of Medicare Part D redesign in the United States. Medicare Part D redesign is expected to have had a negative impact on sales of some other oncology drugs like Xtandi and Lorbrena.
Among the ADCs added from the 2023 acquisition of Seagen, while strong demand trends are likely to have pulled up sales of Padcev, competitive pressure in the United States is expected to have hurt sales of Adcetris. A one-time benefit from a transition to a wholesale distribution model for Seagen products pulled up Padcev’s sales in the second quarter, which will be absent in the third quarter.
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars are likely to have risen in the third quarter.
Pfizer should also provide updates on its oncology candidates in late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin on the third-quarter conference call.
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor Keytruda and PARP inhibitor Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales. Keytruda’s sales rose 6.6% to $15.1 billion in the first half of 2025.
Bristol-Myers’ key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 9% to $4.82 billion in the first half of 2025.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 1.0% so far this year against an increase of 8.0% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.45 forward earnings, lower than 15.89 for the industry and the stock’s 5-year mean of 10.62.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $3.11 per share to $3.12 per share, while that for 2026 has gone up from $3.09 to $3.10 per share over the past 60 days.
Image: Bigstock
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Key Takeaways
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics.
The addition of Seagen in 2023 strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in the first half of 2025.
Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025. Investors will be keen to know how its oncology segment performed in the third quarter when the company announces results on Nov. 4.
Pfizer’s oncology sales in the third quarter are expected to have been driven by higher sales of key drugs like Xtandi, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance.
Sales of Ibrance are likely to have declined due to continued competitive pressure across markets, generic entry in select international markets, and the impact of Medicare Part D redesign in the United States. Medicare Part D redesign is expected to have had a negative impact on sales of some other oncology drugs like Xtandi and Lorbrena.
Among the ADCs added from the 2023 acquisition of Seagen, while strong demand trends are likely to have pulled up sales of Padcev, competitive pressure in the United States is expected to have hurt sales of Adcetris. A one-time benefit from a transition to a wholesale distribution model for Seagen products pulled up Padcev’s sales in the second quarter, which will be absent in the third quarter.
Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars are likely to have risen in the third quarter.
Pfizer should also provide updates on its oncology candidates in late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin on the third-quarter conference call.
Competition in the Oncology Space
Other large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor Keytruda and PARP inhibitor Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales. Keytruda’s sales rose 6.6% to $15.1 billion in the first half of 2025.
Bristol-Myers’ key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 9% to $4.82 billion in the first half of 2025.
PFE’s Price Performance, Valuation and Estimates
Pfizer’s stock has declined 1.0% so far this year against an increase of 8.0% for the industry.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.45 forward earnings, lower than 15.89 for the industry and the stock’s 5-year mean of 10.62.
The Zacks Consensus Estimate for 2025 earnings has risen from $3.11 per share to $3.12 per share, while that for 2026 has gone up from $3.09 to $3.10 per share over the past 60 days.
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.